Payment overview · 2025
General Payments
$7,998.64
84 reported records · 24 companies
Healthcare provider profile · identity verified
Stephen Troy Smith, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · SURPRISE, AZ · NPI 1063632149
Verified facts
What the public records show
CMS Open Payments records show Stephen Troy Smith, MD received $7,998.64 in general payments during 2025 across 84 reported records.
Penumbra, Inc. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,644.36 | 33.1% | 11 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $1,666.66 | 20.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,569.36 | 19.6% | 16 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $622.93 | 7.8% | 12 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $359.22 | 4.5% | 7 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $316.70 | 4.0% | 5 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $151.53 | 1.9% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $101.89 | 1.3% | 6 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $68.60 | 0.9% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $65.77 | 0.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $54.35 | 0.7% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $52.34 | 0.7% | 3 | 2025 |
| Koya Medical, Inc. | Unresolved — no canonical attribution shown | $46.45 | 0.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.20 | 0.5% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $34.62 | 0.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.05 | 0.4% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $31.69 | 0.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.50 | 0.4% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $25.81 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.58 | 0.2% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $17.33 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.02 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.73 | 0.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $13.95 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,216.96 | 74 |
| Travel and Lodging | $2,115.02 | 9 |
| Grant | $1,666.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,644.36 | 11 | 2025 |
Source payment records
|
|||||
| PIVOX OBLIQUE LATERAL SPINAL SYSTEM Normalized: pivox oblique lateral spinal system |
Device | Medtronic, Inc. | $817.64 | 8 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $622.93 | 12 | 2025 |
Source payment records
|
|||||
| ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY Normalized: anteralign spinal system with titan nanolock surface technology |
Device | Medtronic, Inc. | $291.85 | 2 | 2025 |
Source payment records
|
|||||
| AQUAMANTYS(TM) Normalized: aquamantys tm |
Device | Medtronic, Inc. | $277.94 | 2 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $176.59 | 3 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $169.54 | 3 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $143.80 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $142.54 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $114.67 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $103.05 | 3 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $103.05 | 3 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $101.89 | 6 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $79.58 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $68.60 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $54.35 | 2 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $52.34 | 3 | 2025 |
Source payment records
|
|||||
| DAYSPRING Normalized: dayspring |
Device | Koya Medical, Inc. | $46.45 | 3 | 2025 |
Source payment records
|
|||||
| KOYA MEDICAL Normalized: koya medical |
Device | Koya Medical, Inc. | $46.45 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $37.22 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $34.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $31.69 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $28.55 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Pico 14 Normalized: pico 14 |
Device | Smith+Nephew, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $12.39 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $7.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 188 | 70 |
| Xarelto | Rivaroxaban | 106 | 18 |
| Cilostazol | Cilostazol | 42 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 20 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,998.64 · 84 records | Penumbra, Inc. | AFX2 Bifurcated Endograft System, ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY, AQUAMANTYS(TM), ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, Alto Abdominal Stent Graft System, Barostim Neo System, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CARTO 3, CGuard Prime Carotid Stent System, COOK, DAYSPRING, ENDOCROSS Device, ENDURANT IIS, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWTRIEVER, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Thoracic Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, General - Therapies, General - Vascular Intervention, IN.PACT ADMIRAL, INSPIRE, Indigo System, KOYA MEDICAL, Kerendia, LEQVIO, LUTONIX Drug Coated Balloon, PIVOX OBLIQUE LATERAL SPINAL SYSTEM, Pico 14, RENASYS TOUCH, REPATHA, SYMPHONY CATHETER, Torus Stent Graft System, Wegovy, ZENITH SPIRAL-Z | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error